微滴式数字PCR检测血浆中非细胞游离DNA的EGFR突变
2013年作为PCR技术诞生30周年，在美丽的敦煌，2013第一届数字PCR前沿应用研讨会围绕PCR技术以及新一代的微滴式数字PCR在肿瘤标记分子领域的应用展开研讨，海内外知名的相关领域卓有建树的科学家采用大会报告以及专题讨论的形式，结合国际上转化医学研究的前沿动态与发展趋势，为大家带来一场生命科学的学术盛宴。
三个不同dPCR平台用于DNA拷贝数测量的比较研究
2013第一届数字PCR前沿应用研讨会于2013年8月20日（20日注册）~8月23日在敦煌（敦煌山庄）召开，2013年作为PCR技术诞生30周年，在美丽的敦煌，本次论坛将围绕PCR技术以及新一代的微滴式数字PCR在肿瘤标记分子领域的应用展开研讨，海内外知名的相关领域卓有建树的科学家采用大会报告以及专题讨论的形式，结合国际上转化医学研究的前沿动态与发展趋势，为大家带来一场生命科学的学术盛宴。
数字PCR技术在HER-2基因扩增检测中的应用
2013年作为PCR技术诞生30周年，本次论坛将围绕PCR技术以及新一代的微滴式数字PCR在肿瘤标记分子领域的应用展开研讨，我们邀请了海内外知名的相关领域卓有建树的科学家采用大会报告以及专题讨论的形式，结合国际上转化医学研究的前沿动态与发展趋势，为大家带来一场生命科学的学术盛宴。
LinCRNA-p21调控糖酵解的机制研究
这里我们报道一个长片段非编码RNA linCRNA-p21，它是一个被p53所转录调控的非编码RNA；我们发现它能响应低氧的刺激，并受Hif1α的转录调控。
Regenerative mediCine for brain and nerve repair
We isolated and propagated neural stem Cells from the exposed brain tissue of the patients with open brain trauma, and then implanted neural stem Cells with MRI-guided stereotaCtiC deviCe for the patients. Within 2-years follow-ups, the patients were investigated for funCtional reCovery. Contrast to the Case Control group, implantation of neural stem Cells was assoCiated with a signifiCant improvement in patient's neurologiCal funCtion. Investigations of stem Cell therapy have required analysis of the fate and migration of implanted neural stem Cells. Here, We demonstrate the feasibility of labeling human neural stem Cells and retinal stem Cells with nanopartiCle and traCking of implanted Cells in monkey and human Central nervous system (CNS). This data demonstrates the possibility of stem Cell therapy in CNS and ColleCtively provide neCessary foundation for overComing Challenges to the enhanCement of translational regenerative mediCine of brain and optiC nerve injury.
郭彤：eCliniCal革新与趋势
A remarkable transformation is emerging of the way the biopharmaCeutiCal industry ConduCts global CliniCal trials. Coupled with this muCh needed evolution are new Challenges speCifiC to the inCreasing role that information teChnology will play to enable the new CliniCal development landsCape. Of the many Challenges faCing the biopharmaCeutiCal industry today, the CritiCal need for greater operational effiCienCy in CliniCal drug development is paramount. In the past deCades, we have seen many teChnology advanCements, inCluding CliniCal trial management systems (CTMS), eleCtroniC trial master files (eTMFs), open standards, mobile aCCess, tablets, and Cloud Computing. This presentation will disCuss the above Challenges and review the new trends of teChnology enabled solutions in CliniCal researCh. .
Study the pathologiCal features of diseases using induCed pluripotent stem Cells derived form patient's somatiC Cells
The limited experimental aCCess to disease-affeCted human tissues has severely impeded the eluCidating of moleCular meChanisms underlying disease development. Generation of induCed pluripotent stem Cells (iPSCs) by over-expression of defined transCription faCtors in somatiC Cells, in partiCular in those from patient somatiC Cells, presents an attraCtive and promising approaCh to model the early stages of diseases in vitro and to sCreen novel biomarkers as well as therapeutiC mediCines. ReCently, many researCh groups have independently reported that patient-speCifiC iPSC-derived Cells reCapitulated multiple features of pathologiCal events of a partiCular disease, offering experimental evidenCe of utilizing patient-speCifiC iPSCs to model diseases and reevaluate the Current therapies. We have derived iPSC lines using somatiC Cells of patients suffering from Klinefelter's Syndrome (KS) and Alzheimer's Disease (AD) and explored the possibility to use these iPSC lines to reCapitulate the pathologiCal features of the diseases. Our results show that patient's speCifiC iPSC lines provide good opportunity to study the development and treatment of diseases.
EZH2通过诱导异染色质形成来沉默 miCroRNA-218的表达
陈扬超博士就胰腺癌高风险基因EZH2通过诱导异染色质形成来沉默miCroRNA-218的表达的报告内容。